Bondronat 2 Mg/2 Mℓ, 2 mg/2 mℓ, 6 mg/6 mℓ Injection
PDF Leaflet Revision Date: 24 October 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of tumour-induced hypercalcaemia and prevention of skeletal complications in breast cancer with bone metastases.
Dosage (summary)
6 mg IV every 3-4 weeks; adjust for renal impairment.
Onset of Action / Duration
Onset: 7 days, Duration: 18-26 days
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding due to lack of clinical experience.
Key Drug Interactions
- Aminoglycosides
- Calcium-containing solutions
Contraindications
- Hypersensitivity to ibandronic acid
- Hypocalcaemia
Common side effects
- Hypocalcaemia
- Headache
- Dizziness
- Asthenia
- Fever
Counselling Points
- Ensure adequate hydration before infusion
- Monitor for signs of jaw osteonecrosis
- Report any thigh or groin pain immediately
Serious warnings
- Anaphylactic reactions
- Osteonecrosis of the jaw
- Atypical femoral fractures
Important Disclaimer
The Bondronat 2 Mg/2 Mℓ, 2 mg/2 mℓ, 6 mg/6 mℓ Injection professional information leaflet below is the property of Adcock Ingram and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
